Exosomes as an emerging biological nanoplatform in the management of Alzheimer's disease: Breakthroughs and bottlenecks
Authors:
- Vikas KambleVKVikas Kamble
- Kaustubh Ajit KolekarKKKaustubh Ajit Kolekar
- Swati DabholeSDSwati Dabhole
- Bushra BashirBBBushra Bashir
- Popat S. KumbharPKPopat S. Kumbhar
- John DisouzaJDJohn Disouza
- Vandana B. PatravaleVPVandana B. Patravale
- 16 May 2026
- journal article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 123
Abstract
No abstract availableThis publication has 160 references indexed in Scilit:
- Extracellular vesicles from human‐induced pluripotent stem cell‐derived neural stem cells alleviate proinflammatory cascades within disease‐associated microglia in Alzheimer's diseaseJournal of Extracellular Vesicles, 2024
- The role of microglia in Alzheimer's disease and progress of treatmentIbrain, 2022
- The Future Is P-Tau—Anticipating Direct-to-Consumer Alzheimer Disease Blood TestsJAMA Neurology, 2021
- Extracellular vesicle biomarkers of Alzheimer's disease associated with sub‐clinical cognitive decline in late middle ageAlzheimer's & Dementia, 2020
- Inflammation-Stimulated Mesenchymal Stromal Cell-Derived Extracellular Vesicles Attenuate InflammationStem Cells, 2017
- The Multifaceted Functions of Exosomes in Health and Disease: An Overview2017
- GMP Facilities for Clinical Cell Therapy Product Manufacturing: A Brief Review of Requirements and Design Considerations2016
- Low neural exosomal levels of cellular survival factors in Alzheimer's diseaseAnnals of Clinical and Translational Neurology, 2015
- Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the BrainArchives of Neurology, 2009
- Biochemical Diagnosis of Alzheimer Disease by Measuring the Cerebrospinal Fluid Ratio of Phosphorylated tau Protein to β-Amyloid Peptide42Archives of Neurology, 2003